Endometriosis is a complex disorder in which the tissue that normally lines the inside of the uterus grows outside the uterus. This displaced tissue responds to hormonal changes and breaks down and bleeds with each menstrual cycle. It commonly affects women during their reproductive years, usually starting in the late teens or early 20s. Symptoms of endometriosis may include painful periods, pain during or after sex, excessive bleeding, and infertility. The endometriosis treatment market consists of drugs and surgical procedures to treat endometriosis effectively. Medications that are commonly used to treat endometriosis include hormonal medications such as oral contraceptives or progestins which can help reduce menstrual bleeding and pain. Surgeries are also recommended for severe cases to destroy or remove the endometrial growths and scar tissue.
The global endometriosis treatment market is estimated to be valued at US$ 3,260.6 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030. Growing awareness about endometriosis, increasing cases of delayed childbearing, non-invasive surgical procedures are fueling the market growth.
Key Takeaways
Key players operating in the endometriosis treatment market are Astra Zeneca Plc., Eli Lilly and Company, AStellas Pharma, Bayer AG, Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc. Astra Zeneca and Eli Lilly are the leading players focusing on novel drug development and strategic collaborations for enhancing their product portfolios.
Key opportunities in the market include raising awareness and improving care for endometriosis. Government support and targeted public awareness campaigns are necessary to increase disease recognition and improve access to advanced treatment options.
Globally, there is high unmet need in developing regions due to lack of awareness and limited medical facilities. Leading players are expanding their geographic footprints in emerging countries of Asia Pacific and Latin America through collaborations with local diagnostic centers and pain clinics.
Market drivers and restrain
One of the major drivers of endometriosis treatment market is growing awareness about the disease and its treatment options. Endometriosis awareness month observed in March every year helps educate women about its symptoms and need for early diagnosis. Also, advancement in minimally invasive surgical techniques such as laparoscopy is driving the adoption of surgical treatment for endometriosis.
However, high cost of endometriosis treatment poses a major challenge. Treatment involves significant expenses for medications, specialized surgical procedures and fertility treatments if required. Lack of insurance coverage and expensive branded drugs especially in developing countries limit the market growth to some extent.
Segment Analysis
Hormonal drugs is the dominating sub segment under drug therapy segment. This is because hormonal drugs are widely prescribed by physicians as first line treatment for endometriosis as they help in alleviating symptoms and minimally invasive surgeries are preferred over major invasive surgeries. Laparoscopy surgery is the dominating sub segment under the surgery segment. This is because laparoscopy surgeries have minimal incisions and faster recovery time compared to open surgeries making it the preferred choice of treatment among patients and physicians.
Global Analysis
North America dominates the global endometriosis treatment market currently and is expected to continue its dominance during the forecast period. This is attribute to the advanced healthcare infrastructure, adoption of minimally invasive procedures, and awareness regarding endometriosis in the region. Asia Pacific is expected witness the fastest growth during the forecast period owing to rising incidences of endometriosis, growing medical tourism, and increasing healthcare expenditure in the region.
